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Abstract: For optimal efficacy, an inhaler should deliver doses consistently and be easy for 
patients to use with minimal instruction. The delivery characteristics, patients’ correct use, and 
preference of two single-dose dry powder inhalers (Breezhaler and HandiHaler) were evaluated 
in two complementary studies. The first study examined aerodynamic particle size distribution, 
using inhalation profiles of seven patients with moderate to very severe chronic obstructive 
pulmonary disease (COPD). The second was an open-label, two-period, 7-day crossover study, 
evaluating use of the inhalers with placebo capsules by 82 patients with mild to severe COPD. 
Patients’ correct use of the inhalers was assessed after reading written instructions on Day 1, and 
after training and 7 days of daily use. Patients’ preference was assessed after completion of both 
study periods. Patient inhalation profiles showed average peak inspiratory flows of 72 L/minute 
through Breezhaler and 36 L/minute through HandiHaler. For Breezhaler and   HandiHaler, fine 
particle fractions were 27% and 10%, respectively. In the second study,   correct use of Breezhaler 
and HandiHaler was achieved by .77% of patients for any step after 7 days; 61% of patients 
showed an overall preference for Breezhaler and 31% for HandiHaler (P = 0.01).
Breezhaler is a low-resistance inhaler suitable for use by patients with a range of disease severities. 
Most patients used both inhalers correctly after 7 days, but more patients showed an overall 
preference for the Breezhaler compared with the HandiHaler. These are important factors for 
optimum dose delivery and successful COPD management.
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Introduction
A patient’s ability to use an inhaler correctly and their preference for the inhaler are 
both important factors in selecting an appropriate treatment for chronic obstructive 
pulmonary disease (COPD).1 Incorrect handling of inhalation devices is common in 
COPD and is influenced not only by patient-related factors (eg, physical ability) but 
also by the type of inhaler prescribed and the adequacy of patient education.2–4  Poor 
handling and inhalation technique may result in suboptimal drug delivery to the lower 
airway,2,5–7 which can ultimately reduce compliance and prevent successful disease 
management.8,9
The aerodynamic size of drug particles generated by inhalers is critical in 
  determining the distribution and deposition of drug within the lung, with the fine 
particle fraction or FPF (defined as fraction of particles less than 5 µm in diameter) 
generally considered optimum to deposit in the bronchi and alveoli. Thus, dose delivery 
from a dry powder inhaler (DPI) depends not only on correct handling and inhalation, 
but also on the inhaler’s internal resistance and its ability to generate sufficient fine International Journal of COPD 2011:6 submit your manuscript | www.dovepress.com
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particles to ensure drug deposition in the lower airway.10 
High-resistance devices require greater effort by the patient 
to achieve inspiratory flows adequate to ensure FPF dose 
delivery,11 and some patients with significant pulmonary 
disease cannot generate these flows.12,13
Inhaled long-acting bronchodilators are used for the 
treatment of patients with moderate and more severe COPD,14 
with two agents available for once-daily administration. 
Indacaterol is a novel, inhaled, once-daily, ultra-long-acting 
β2-agonist15 delivered by a single-dose DPI known as the 
Breezhaler® in some countries, and approved in more than 
40 countries for maintenance treatment in COPD. The 
other once-daily inhaled bronchodilator is the anticholin-
ergic, tiotropium, delivered by a single-dose DPI called the 
HandiHaler®.
This paper presents the results of two complementary 
studies. The first was an in vitro study evaluating the dose 
delivery characteristics from the single-dose DPIs used with 
indacaterol (Onbrez® Breezhaler® [Novartis Pharma AG, 
Basel, Switzerland]) and tiotropium (Spiriva®   HandiHaler® 
[Boehringer-Ingelheim, Ingelheim, Germany]). The 
two inhalers were compared under a range of simulated 
inspiratory flow conditions modeled from data obtained 
from COPD patients with disease severities ranging from 
mild to severe. The second study assessed patients’ correct 
use and preference for Breezhaler and HandiHaler using 
placebo capsules.
Methods
In-vitro dose delivery study
The aerodynamic particle distribution of indacaterol 150 µg 
via Breezhaler and tiotropium 18 µg via HandiHaler was 
measured using a standard Next Generation Impactor (NGI, 
MSP Corporation, Shore view, MN) with pre-separator and 
induction port coupled to a flow-volume simulator (Figure 1). 
Neutral sum air flow at experimental rest was required to 
facilitate particle generation during the simulated breathing 
maneuvers and was achieved by an auxiliary air supply at 
the mixing inlet and vacuum pump at the impactor outlet 
at 100 L/minute and 60 L/minute, respectively, for the 
Breezhaler and HandiHaler. The patients’ breathing patterns 
were reproduced at the mouthpiece of the DPIs by modulating 
the air flow using the computer-controlled flow-volume 
simulator. Three replicate measurements were obtained for 
each simulated patient flow profile, using a new DPI for each 
determination. The simulated flow profiles closely resembled 
the original patient flow profiles with ,3% mean relative 
difference over all flow values.
Seven patient inhalation flow profiles were chosen from 
a group of profiles obtained from 28 patients. The profiles 
were selected to cover disease severities from moderate to 
severe and a representative range of patient age, gender and 
airflow obstruction. In addition, the technical specification 
of the experimental apparatus determined that the selected 
profiles were within maximum peak inspiratory flows of 
Mixing inlet
DPI and adapter
Valve
Vacuum pump Flow meter
Flow/volume simulator
Flow meter
Compressed air supply
60 L/min (HandiHaler)
100 L/min (Breezhaler)
60 L/min (HandiHaler)
100 L/min (Breezhaler)
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M
Figure 1 Experimental set-up with flow/volume simulator.
Abbreviation: DPI, dry powder inhaler.International Journal of COPD 2011:6 submit your manuscript | www.dovepress.com
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100 L/minute. This is the maximum possible that can be 
achieved through the NGI in order to measure aerodynamic 
particle size distribution when simulating recorded patient 
flow patterns.
Quantification of indacaterol and tiotropium depositions 
from the NGI analysis was performed using high-performance 
liquid chromatography on two samples from each NGI 
component. Fine particle dose and particle size (defined by 
median mass aerodynamic diameter) were measured and 
geometric standard deviation (GSD) determined. GSD is a 
measure of the variability of the particle diameters within 
the aerosol. An aerosol with a GSD of 1 is described as 
monodisperse (uniform diameter distribution); an aerosol 
with a GSD . 1.2 is heterodisperse (heterogeneous particle 
distribution).16
Based on the results of the particle size analysis, the 
theoretical respiratory tract deposition (extrathoracic, repre-
senting the portion ‘lost’ through oropharyngeal deposition, 
versus intrathoracic, delivered to the lower airways) for each 
of the patient breathing profiles was estimated using a semi-
empirical deposition model for healthy lungs.17
The in vitro dose delivery study was carried out at Inamed 
Research GmbH and Co KG, Gauting, Germany.
Assessment of patients’ correct  
use of, and preference for, inhalers
This was a multicenter study conducted in Canada and 
the USA. The protocol was approved by the appropriate 
institutional review board for each participating center 
(Institutional Review Board Services, Aurora, Ontario L4G 
0A5, Canada; Quorum Review, Inc., Seattle WA 98101, 
USA; Dean Institutional Review Board, Middleton WI 
53562, USA).
Patients
The study enrolled co-operative male and female patients 
aged $40 years with a clinical diagnosis of mild to severe 
COPD18 (post-bronchodilator forced expiratory volume in 1 
second [FEV1] .30% predicted; FEV1/forced vital capacity 
, 70%) and smoking history $10 pack-years. The patients 
required use of inhaled medication in the management of their 
COPD, but had no previous experience of either study inhaler 
(or the similar DPI Foradil® Aerolizer® [Novartis Pharma AG, 
Basel, Switzerland] used to administer the twice-daily bron-
chodilator formoterol). Patients gave their written informed 
consent before any assessment was performed.
study design
This was an open-label, multicenter, two-period, 7-day 
crossover study (Figure 2). Patients used Breezhaler or 
  HandiHaler with placebo capsules once daily each for 7 days 
in random sequence, in addition to their usual treatment. 
On Day 1, patients were asked to read written instructions 
for correct use of the inhaler, similar to that provided by the 
manufacturers with the prescribed medications, and had 30 
minutes to practice using the inhaler (without the capsule); 
they were given no verbal training or demonstration at this 
time. Patients were then given the blister containing the 
capsules and asked to demonstrate their use of the inhaler, 
under the observation of two trained respiratory assessors. 
This provided an assessment of first use on the basis of writ-
ten instructions for use only.
The same assessors recorded each patient’s ability 
to perform each of the 21 steps required for correct use 
of Breezhaler and the 19 steps for HandiHaler, using an 
assessment checklist for correct use prepared specifically for 
this study (for details of the checklists, see Table 4, Results). 
7 days 7 days
Day 1 Day 7 Day 8 Day 14
Breezhaler with placebo capsules
HandiHaler with placebo capsules HandiHaler with placebo capsules
Breezhaler with placebo capsules
Written instruction
Practice (30 min)
Assessment
Assessment
Assessment
Preference
questionnaire
Training and demo
Written instruction
Practice (30 min)
Assessment
Training and demo
•
•
•
•
•
•
•
• •
•
•
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Steps were classed as correct (‘yes’ or ‘fully completed’) or 
incorrect (‘no’ or ‘not fully completed’). For each inhaler, 
two steps were identified as critical for appropriate dose 
delivery: full release of the piercing buttons (allowing cap-
sule rotation), and exhalation away from the mouthpiece 
before inhalation. Study center personnel then trained the 
patients verbally and demonstrated (without capsules) how 
to use the inhaler properly before the patients went home. 
Training was standardized across the study centers. These 
procedures were repeated at the start of the second study 
treatment period. At the end of each treatment period (ie, 
on Day 7 of each period), patients’ correct inhaler use and 
inhalation technique were re-assessed by the same assessors. 
After the assessment at the end of the second treatment-
period, patients were given both inhalers used during the 
study and had a few minutes to re-familiarize themselves 
with the two inhalers. They were then asked to complete the 
patient preference questionnaire (for questionnaire details, 
see Table 5, Results). The handling assessment checklist 
and preference questionnaire were developed by the study 
sponsor. In the absence of available validated assessment 
tools, the handling assessment checklist and preference 
questionnaire were developed using the patient information 
leaflets for the inhalers and previously published studies 
investigating inhaler use, and were not validated.
Objectives and outcomes
The primary objective of this study was to assess patients’ 
correct use of the two inhalers after 7 days of daily use, ie, 
under preferable conditions where the patient has read the 
instructions for use and has received verbal training and 
demonstration of correct use. Secondary objectives included 
the assessment of correct use after reading written instruc-
tions on Day 1, the performance of the two critical steps 
on Days 1 and 7, and patients’ preference between the inhalers. 
The comparison of the total handling scores, calculated from 
the device handling assessment checklists, and each item of 
the preference questionnaire, were exploratory objectives.
statistical methods
Results for each step of the device handling assessment 
checklist were summarized by inhaler type as number and 
percentage of patients. A step was classified as correct if 
the response was either ‘yes’ or ‘fully completed’. If the 
responses differed between the assessors, the step was 
classed as incorrect. For each patient, a total handling score 
was calculated as the number (percentage) of checklist items 
with correct use out of the total number of items. The total 
handling scores for the two inhalers were summarized as 
percentages and compared using a mixed analysis of vari-
ance model (Stat Proc Mixed) with fixed effects for period 
and inhaler and a random effect for patient. The difference 
in total handling score is presented with 95% confidence 
intervals (CIs) and associated P-value. Responses to each 
question in the preference questionnaire were summarized 
by inhaler type as number and percentage of patients. For 
questions eliciting a preference between the two inhalers a 
Mainland-Gart test was performed to allow for period effects, 
ignoring patients showing no preference. For responses on a 
10-point scale, a mixed-model analysis of variance was used   
as described for the total handling score analysis.
A formal sample size calculation was not performed, 
because the study was exploratory in nature. The total number 
of 80 patients was chosen based on previous studies that had 
included approximately 60–70 patients.19,20
Results
In-vitro dose delivery study
A group of 28 inhalation profiles was reviewed and seven 
patient inhalation profiles were selected to be representative 
of a COPD population, including moderate and severe 
stages of COPD, an approximately equal number of males 
and females, and a range of ages and inhalation variables 
(Table 1 and Figure 3). The mean FPF was 26.8% of the 
150 µg label claim for Breezhaler, while the mean FPF 
from the HandiHaler was 9.8% of the label claim (18 µg) 
(Table 2). The two inhalers generated particles of similar 
uniformity of size, but the mean size of the drug particles 
from the Breezhaler was smaller than those generated by the 
HandiHaler (3.2 µm compared with 3.9 µm).
Mean estimated intrathoracic drug deposition as a 
percentage of the mean delivered dose (Table 2) was 31% 
for the Breezhaler and 22% for the HandiHaler (Figure 4). 
Mean estimated extrathoracic drug deposition was 57% for 
Breezhaler and 71% for HandiHaler.
Assessment of patients’ correct use  
of, and preference for, inhalers
Eighty-three patients with COPD severities ranging from 
mild to severe were randomized. One patient was ran-
domized in error and left the study before any Day 1 
  procedures had been carried out. This patient was not 
included in the analysis population, which comprised 
82 patients (Table 3).International Journal of COPD 2011:6 submit your manuscript | www.dovepress.com
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Table 1 Patient demographics and derived inhalation variables through the two inhalers
Patient  
no.
Age (yr) Gender FEV1  
(% pred.)
COPD DP  
(cmH2O)
PIF  
(L/minute)
IV (L) IT 
(seconds)
BH HH BH HH BH HH BH HH
1 74 Male 69 Moderate 24 31 80 34 2.2 1.9 2.5 6.3
2 69 Male 39 severe 35 58 97 47 2.1 1.6 1.9 3.0
3 79 Male 58 Moderate 8 14 47 23 1.3 1.5 3.0 6.1
4 70 Female 74 Moderate 9 15 48 24 1.7 1.4 3.2 5.0
5 52 Female 68 Moderate 37 44 99 41 2.0 1.8 1.7 3.8
6 76 Female 66 Moderate 15 34 64 36 1.0 1.3 1.3 3.1
7 71 Female 49 severe 19 61 72 48 1.8 1.5 2.0 2.3
Average 70 – 60 – 21 37 72 36 1.7 1.6 2.2 4.2
Abbreviations: FeV1, forced expiratory volume in 1 s; DP, pressure drop across inhaler; PIF, peak inspiratory flow; IV, inhaled volume; IT, inhalation time; BH, Breezhaler; 
hh, handihaler; yr, years.
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Figure 3 Individual inhalation flow profiles for the selected patients through (A) Breezhaler and (B) handihaler.
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Figure 4 Theoretical intrathoracic drug deposition as a percentage of delivered dose.
Abbreviation: sD, standard deviation.
Table 2 Characteristics of aerosols generated using patient inhalation profiles representative of moderate to severe COPD
Patient  
no.
Breezhaler HandiHaler
DD  
(μg)a
FPD  
(μg)b
FPF  
(%)c
MMAD  
(μm)d
GSDe DD  
(μg)a
FPD  
(μg)b
FPF  
(%)c
MMAD  
(μm)d
GSDe
1 112 46.6 31.1 3.1 1.9 7.9 1.7 9.6 3.9 1.9
2 113 47.8 31.9 3.0 1.9 8.0 1.9 10.4 3.7 1.8
3 83 27.1 18.0 3.5 2.0 6.7 1.4 7.6 4.4 1.8
4 96 32.6 21.7 3.5 1.9 7.8 1.8 10.0 4.2 1.8
5 113 47.9 31.9 2.9 1.9 6.9 1.7 9.4 3.8 1.8
6 87 33.4 22.3 3.2 2.0 8.2 2.0 10.9 3.8 1.8
7 111 45.8 30.5 3.0 1.9 7.8 2.0 10.9 3.9 1.9
Mean (sD) 102.0  
(14.53)
40.2  
(8.70)
26.8  
(5.80)
3.2  
(0.22)
2.0  
(0.07)
7.6  
(0.82)
1.8  
(0.30)
9.8  
(1.65)
3.9  
(0.29)
1.8 
(0.06)
Notes: Data are means for each patient profile. aDD, delivered dose (µg per capsule); bFPD, fine particle dose (particles #4.7 µm in diameter). cFPF, fine particle fraction 
(particles #4.7 µm in diameter) as % of label claim dose (indacaterol 150 µg via Breezhaler, tiotropium 18 µg via handihaler); dMMAD, median mass aerodynamic diameter 
(ie, the size of drug particles); egsD, geometric standard deviation, a measure of the uniformity of particle size.
Abbreviation: sD, standard deviation.
Patients’ correct inhaler use
The results for each checklist item on Days 1 and 7 are 
shown in Table 4. For most steps, the proportion of patients 
correctly performing the step increased from Day 1 to Day 7. 
On Day 7, each step was performed correctly by most patients 
(78%–100% for Breezhaler; 81%–100% for HandiHaler). For 
the critical step of fully releasing the button before inhalation, 
the Breezhaler score was similarly high on both days (93%, 
96%), while for the HandiHaler the proportion of patients 
correctly completing this step changed by 11% from 88% 
(Day 1) to 99% (Day 7). The other critical step (breathing out 
away from the inhaler before inhalation) was completed cor-
rectly on Day 7 by 85% of patients with Breezhaler and 81% 
of patients using the HandiHaler. The percentage of patients 
without a critical error was 81% and 83% on Days 1 and 7, 
respectively, for Breezhaler, and 70% and 81% on Days 1 
and 7, respectively, for HandiHaler.
Total handling scores on Day 7 (least squares means) were 
93.5% for Breezhaler and 94.4% for HandiHaler, a mean 
  difference of −1.0 (95% CI −3.0 to 1.1; P = 0.357). On Day 1, 
scores were 91.8% for Breezhaler and 90.6% for HandiHaler, 
a difference of 1.2 (95% CI −1.2 to 3.6; P = 0.333).
Patients’ inhaler preference
The results of the preference questionnaire are presented 
in Figures 5 and 6 and Table 5. In response to the overall 
preference question, more patients chose Breezhaler as their 
preferred inhaler to use on a daily basis (61% of patients) 
compared with HandiHaler (31%) (P = 0.010). For individual 
responses, Breezhaler was preferred for ease of opening the International Journal of COPD 2011:6 submit your manuscript | www.dovepress.com
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cap and mouthpiece (both P , 0.001), closing the mouthpiece 
after inserting the capsule (P = 0.005) and holding the inhaler 
(P , 0.001). There were no statistically significant preferences 
for HandiHaler. The mean scores for the items scored on a 1–10 
scale (comfort of inhalation, simplicity of use and confidence 
in successful intake of medication) were slightly greater with 
Breezhaler than with HandiHaler, and the differences in mean 
score were statistically significant (Figure 6).
Discussion
Breath actuation was a major advantage when DPIs were   
developed, overcoming problems that patients had in 
coordinating actuation and inhalation with pressurized 
metered-dose inhalers. However, breath actuation also meant 
that patients had to generate an inspiratory effort to overcome 
the internal resistance of the DPIs. Breezhaler has a lower 
internal resistance than HandiHaler (specific airflow resis-
tances of 2.2 and 5.1 × 10−2 kPa½ L−1 minute, respectively).21 
Thus, the Breezhaler requires less inspiratory effort to achieve 
a given inspiratory flow or, as reflected in the inspiratory 
flow profiles, permits a higher inspiratory flow for a given 
effort. We measured the inhalation patterns of 28 patients, 
subsequently using the profiles of seven patients as a result of 
various exclusion criteria, the main one being the 100 L/minute 
calibration limit of the measuring equipment. This limited the 
study to the potentially ‘poorer’ end of the inspiratory profiles 
for Breezhaler (as the low resistance permits inspiratory flows 
higher than the set limit) but not for the HandiHaler, since 
achievable inhalation flow rates for this higher-resistance 
inhaler would tend to be well within the calibration limit.
Although certain characteristics are desirable in terms of 
inhaler design, our in vitro comparisons of particles generated 
by the two inhalers should not be extrapolated directly to the 
clinical situation, where therapeutic doses are selected based 
on demonstrated pharmacodynamic responses. The higher FPF 
and the lower extrathoracic deposition of drug delivered by the 
Breezhaler compared with the HandiHaler are examples of such 
desirable properties. The higher FPF with Breezhaler (27%) 
relative to HandiHaler (10%) suggests that a higher propor-
tion of the dose would be delivered to the smaller airways. A 
higher extrathoracic deposition (71% of the dose delivered by 
HandiHaler compared with 57% for Breezhaler) would reflect 
the amount of drug deposited in the mouth and oropharynx 
and swallowed, giving rise to systemic exposure and a risk of 
side effects. However, while particle size is determined by the 
inhaler, the distribution of particles in the lung depends on 
both particle size and inspiratory flow,22 and the bronchodilator 
effect of the drug particles is a complex function of local drug 
concentration, receptor and airway smooth muscle distribu-
tion and the pathology of the disease. While airway smooth 
muscle is relatively sparse in the alveolar region, this is where 
β2-adrenoceptor density is highest.23 A β2-agonist bronchodila-
tor for COPD, this being a disease primarily of the small airways 
and alveoli, would ideally be delivered as small particles (FPF) 
and activate receptors in those regions. Muscarinic receptors on 
airway smooth muscle are located more densely in the lower 
trachea and bronchi than in the smaller airways.24
It was recently shown that patients with a wide range of 
COPD severity, including very severe, are able to generate 
adequate inspiratory flows with Breezhaler and that a consis-
tent dose is delivered irrespective of disease severity and age.21 
COPD patients with more severe airways obstruction have 
been shown to inhale slower through DPIs (compared with 
patients with less severe impairment) and may have problems 
achieving an adequate inspiratory flow through high-resistance 
DPIs.13,25,26 A trend towards increasing patient acceptability 
with decreasing inhaler resistance has been shown, although 
the effect plateaued as resistance continued to decrease.19
Inhaler resistance, although important, is not the only 
factor contributing to the acceptability of inhalers to patients. 
Patients found Breezhaler not only more comfortable to 
Table 3 Patients’ baseline characteristics (n = 82)
Age, years 63.9 (9.21)
Age group, n (%)  
  40–64 years
 
40 (49)
 $ 65 years 42 (51)
Male/female, % 60/40
BMI, kg/m2 29.3 (6.29)
BMI group, n (%)  
  #30.0 kg/m2
 
49 (60)
 . 30.0 kg/m2 33 (40)
COPD severity, n (%)a  
  Mild
 
29 (35)
  Moderate 41 (50)
  severe 10 (12)
Ex-smoker/smoker, % 50/50
smoking history, pack-years 50.4 (27.52)
Duration of inhaled medication, n (%)  
  ,5 years
 
58 (71)
  5–9 years 13 (16)
  10–14 years 5 (6)
 $ 15 years 6 (7)
Post-bronchodilator FeV1, Lb 2.0 ( 0.67)
Post-bronchodilator FeV1, % predictedb 73 (16.7)
Post-bronchodilator FeV1/FVC, %b 60 ( 8.6)
Notes: Data are mean (standard deviation) unless otherwise stated. aData missing 
for two patients whose post-bronchodilator FeV1/FVC was .70%; bFeV1 and FVC 
were measured 10–15 minutes after inhalation of four puffs of salbutamol 100 µg 
(four puffs of albuterol 90 µg).
Abbreviations: BMI, body mass index; FeV1, forced expiratory volume in 1 second; 
FVC, forced vital capacity.International Journal of COPD 2011:6 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
360
Chapman et al
inhale through but also simpler to use, and they were more 
confident that the medication had been taken correctly. 
  Significant differences in scores also favored Breezhaler 
over the   HandiHaler for removing the cap and for open-
ing and closing the mouthpiece. These initial impressions, 
after a relatively short familiarization period, may be very 
important to ensure adherence and continued use, which 
are poor with COPD patients.9,27 It seems intuitive that a 
patient is more likely to use an inhaler that they like and 
find easy to use, although studies in asthma patients have 
failed to show an association between inhaler preference 
and adherence.28,29 However, physical difficulty in handling 
medication has been identified as a significant predictor of 
low adherence.30
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Figure 5 Patient preference for the two inhalers with respect to the different steps in use. 
Notes: **P # 0.01; ***P , 0.001 between the two inhalers.
Table 4 Percentage of patients correctly completing each item of the checklists on Day 1 and Day 7
(a) Breezhaler checklist Day 1 Day 7 (b) HandiHaler checklist Day 1 Day 7
  1. Pull off cap 100.0 100.0   1. Open the cap 98.8 97.5
  2. Open mouthpiece 98.8 100.0   2. Open mouthpiece 96.3 97.5
  3. remove capsule from blister pack 98.8 100.0   3. remove capsule from blister pack 93.8 97.5
  4. Insert capsule in the inhaler 100.0 100.0   4. Insert capsule in the inhaler 98.8 100.0
  5. Close inhaler – click heard 98.8 98.8   5. Close inhaler – click heard 98.8 98.8
  6. Was the mouthpiece facing upwards? 96.3 97.5
  6. Pierce the capsule 95.1 98.8   7. Pierce the capsule 97.5 96.3
  7. Pierced once only 92.7 91.4   8. Pierced once only 95.1 90.0
  8. Click/piercing noise heard by assessor 92.7 100.0   9. Click/piercing noise heard 93.8 95.0
  9. Was inhaler held upright? 89.0 88.9
10. Were both buttons pressed simultaneously? 95.1 97.5
11. release buttons 90.2 97.5 10. release button 88.9 96.3
12.   Were buttons fully released before  
inhalation?a
92.7 96.3 11. Was button fully released before inhalation?a 87.7 98.8
13. Breathe out – not into mouthpiecea 84.1 85.2 12. Breathe out – not into mouthpiecea 80.2 81.3
13. Was inhaler held horizontally during inhalation? 85.2 95.0
14. Inhale the medicine rapidly and steadily 87.8 93.8 14. Inhale the medicine slowly and deeply 88.9 93.8
15.   Were the air inlets unobstructed by fingers? 92.7 91.4 15. Were the air inlets unobstructed by fingers? 91.4 95.0
16. Audible whirring noise 82.9 91.4
17.   hold breath for as long as is comfortable 84.1 77.8 16. hold breath for as long as is comfortable 75.3 86.3
18.   Check upon whether capsule has been fully 
emptied
80.5 77.8
19.   If residue is remaining in capsule, did patient  
close inhaler and repeat steps 13–18
82.1 80.8 17.   Did the patient repeat steps 12–16  
to ensure full dose was taken from capsule?
69.1 83.8
20.   Open inhaler, remove capsule, close inhaler  
and replace cap
95.1 96.3 18. Open cap, remove capsule, close and replace cap 88.9 97.5
21. Was capsule pierced at both ends? 93.9 98.8 19. Was capsule pierced at both ends? 95.1 96.3
Note: aPrespecified as a particularly critical step.International Journal of COPD 2011:6 submit your manuscript | www.dovepress.com
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With the two inhalers evaluated in this study, the pro-
portion of patients completing each step correctly generally 
increased over the 7 days, reflecting the effects of training 
and familiarization. For the critical step of releasing the 
button(s) prior to inhalation, scores were reasonably high 
on both days with Breezhaler (93% on Day 1 and 96% 
on Day 2), but were relatively poor (88%) on Day 1 with 
HandiHaler, increasing 11 percentage points by Day 7. With 
many inhalers, written instructions alone may be inadequate 
for successful use and training and familiarization through 
daily use are required before correct use can be achieved. 
This was also demonstrated by differences of 9%–11% in the 
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Figure 6 Patient preference for the two inhalers with respect to overall comfort, simplicity and confidence in use. 
Notes: *P , 0.05; ***P # 0.001 between the two inhalers. (Preference measured on a 10-point scale from 1 to 10.)
Abbreviation: se, standard error.
Table 5 Patient preference questionnaire results
Breezhaler HandiHaler No preference P-valuec
1)  Questions about the ease and comfort of using the inhalers
(a)  Which is easier to remove/open the cap of the inhaler? 58.0 19.8 22.2 ,0.001
(b)  Which mouthpiece is easier to open? 64.2 9.9 25.9 ,0.001
(c)  Which is easier to insert the capsule in the inhaler? 24.7 44.4 30.9 0.059
(d)  Which is easier to close (after inserting the capsule)? 38.3 14.8 46.9 0.005
(e)  how comfortable is it to inhale medication through the inhaler?a 0.031
    Mean (sD) 8.6 (1.67) 8.0 (2.10)
    Median (range) 9.0 (1.0–10.0) 9.0 (1.0–10.0)
(f)  Which is easier to hold while inhaling the medication? 59.3 21.0 19.8 ,0.001
(g)  Which is easier for removing the empty capsule? 30.9 46.9 22.2 0.136
(h)  Which is easier to close after use? 35.8 23.5 40.7 0.244
(i)  Overall, how simple is it to use the inhaler?a 0.046
    Mean (sD) 8.8 (1.80) 8.2 (1.96)
    Median (range) 9.0 (1.0–10.0) 9.0 (1.0–10.0)
2)  Questions about trust and confidence in using the inhalers
(a)/(b)    Do you use a specific check to ensure you have inhaled  
the medication?b
not testedd
    Any specific check 90.1 81.5
    Listen to vibration/whirring 84.0 71.6
    Other check 58.0 33.3
(c)    How confident are you that you have taken the medication 
successfully?a
0.001
    Mean (sD) 9.1 (1.37) 8.2 (2.29)
    Median (range) 10.0 (4.0–10.0) 9.0 (1.0–10.0)
3)  Question about overall preference
Which of the inhalers would you prefer to use on a daily basis? 60.5 30.9 8.6 0.010
Notes: Data are % of patients unless stated otherwise. aOn 10-point scale from 1 = not at all to 10 = extremely; bPercentages for question 2 (a)/(b) were calculated using the 
full analysis set (Breezhaler, n = 82; handihaler, n = 81); cFor comparison between inhalers; dnot tested, because item did not relate to a preference.International Journal of COPD 2011:6 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
362
Chapman et al
proportion correctly completing other steps with HandiHaler 
(holding inhaler horizontally, breath holding, and the capsule-
removal procedure). Because Day 1 scores were generally 
higher with Breezhaler, the differences between Day 1 and 
Day 7 scores were generally smaller. For the other critical 
step, about 15% of patients using the Breezhaler and 20% 
using the HandiHaler failed to breathe out away from the 
inhaler before inhalation on both Days 1 and 7.
These data highlight areas for focusing educational 
efforts. Continued education and monitoring of inhaler use 
improve adherence and are critical factors to successful 
management, and may well have equal or greater importance 
than inhaler type.1 It is known that initial appropriate use is 
lost over time,19 and continued evaluation of correct inhaler 
use by treating physicians is especially important among older 
patients and those receiving multiple medications.9,30,31
In conclusion, most patients used both inhalers correctly 
after 7 days. Patients preferred the Breezhaler overall and 
scored it more highly than the HandiHaler for the majority 
of questions in the preference questionnaire. Breezhaler is 
a low-resistance inhaler suitable for use by patients with a 
range of disease severities. These are important factors for 
ensuring optimum dose delivery, patient adherence with 
treatment and successful COPD management.
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